Key Takeaway: Aura Biosciences has successfully enrolled 108 patients in its Phase 3 CoMpass trial, surpassing its enrollment target. The company is on track to release topline data in the second half of 2027. Additionally, interim data for bel-sar in non-muscle invasive bladder cancer (NMIBC) suggest promising efficacy and safety, reinforcing its strategic focus on ocular oncology.
Market Sentiment Analysis
POSITIVE FACTORS
Phase 3 CoMpass trial fully enrolled with 108 patients.
Interim NMIBC data shows potential for durable efficacy.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+4%
120-day peak, hindsight
Typical move
7%
average across 5 past catalysts
Cash runway
~20 mo
Low dilution risk
Lead asset
AU-011
Phase 2 · Uveal Melanoma
Full Press Release Details
Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 Strategic operating plan refined to focus on development of bel-sar in ocular oncology Interim NMIBC data reinforce bel-sar’s potential for durable efficacy and favorable safety
Frequently Asked Questions
What is the status of the Phase 3 CoMpass trial?
The Phase 3 CoMpass trial is fully enrolled with 108 patients.
When will topline data be available?
Topline data from the trial is expected in the second half of 2027.
What does interim NMIBC data indicate?
Interim NMIBC data suggests durable efficacy and favorable safety for bel-sar.
What is the focus of Aura's strategic plan?
Aura's strategic plan focuses on developing bel-sar in ocular oncology.